General
Preferred name
mibefradil
Synonyms
MIBEFRADIL DIHYDROCHLORIDE ()
Ro 40-5967 ()
Mibefradil (dihydrochloride) ()
Ro 40-5967 (dihydrochloride) ()
RO 40-5967/001 ()
Posicor ()
Mibefradil hydrochloride ()
Posicor 50 ()
Posicor 100 ()
Mibefradil ()
Mibefradil (hydrochloride) ()
P&D ID
PD009103
CAS
116666-63-8
116644-53-2
Tags
natural product
drug
available
Approved by
FDA
First approval
1997
Drug indication
Glioblastoma multiforme
Vasodilator
Ovarian cancer
Drug Status
investigational
approved
withdrawn
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Marketed formulations contained mibefradil dihydrochloride (PubChem CID 60662). (GtoPdb)
DESCRIPTION Highly selective CaV3.x blocker (Tocris Bioactive Compound Library)
DESCRIPTION Ca2+ channel blocker (T-type) (Tocriscreen Plus)
DESCRIPTION T-type Ca2+ channel blocker (LOPAC library)
DESCRIPTION Ca2+ channel blocker (T-type) (Tocriscreen Total)
DESCRIPTION Mibefradil, a calcium channel blocker, has modest selectivity for T-type Ca2+ channels so that could be used in the treatment of sorts of cardiovascular disease like hypertension and chronic angina pectoris. IC50: 2.7 μM (for T-type). (BOC Sciences Bioactive Compounds)
Cell lines
3
Organisms
2
Compound Sets
26
BOC Sciences Bioactive Compounds
mibefradil-cas-116644-53-2-item-210407
Cayman Chemical Bioactives
15037
ChEMBL Approved Drugs
CHEMBL1534525
CHEMBL45816
ChEMBL Drugs
CHEMBL1534525
CHEMBL45816
Concise Guide to Pharmacology 2017/18
2522
Concise Guide to Pharmacology 2019/20
2522
Concise Guide to Pharmacology 2021/22
2522
Concise Guide to Pharmacology 2023/24
2522
Drug Repurposing Hub
DrugBank
DB01388
DrugCentral
1797
DrugCentral Approved Drugs
1797
DrugMAP
DMU9VDS
EU-OPENSCREEN Bioactive Compound Library
EOS101204
Guide to Pharmacology
2522
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL45816
MedChem Express Bioactive Compound Library
HY-15553A
NPC Screening Collection
ReFrame library
Tocris Bioactive Compound Library
2198
Tocriscreen Plus
2198
Tocriscreen Total
VGSC-DB
NA0083
NA0084
NA0085
NA0086
NA5932
Withdrawn 2.0
DB01388
ZINC Tool Compounds
ZINC000003782486
External IDs
49
Properties
(calculated by RDKit )
Molecular Weight
495.29
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
11
Ring Count
4
Aromatic Ring Count
3
cLogP
5.27
TPSA
67.45
Fraction CSP3
0.52
Chiral centers
2.0
Largest ring
6.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Selectivity
T-type
Target
Calcium Channel
ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Primary Target
CaV3.x Channels (T-type)
MOA
Blocker
T-type calcium channel blocker
ATC
C08CX01
VGSC Target
Nav1.7
Nav1.2
Nav1.4
Nav1.5
Nav1.9
Solubility
10 mM in DMSO
Source data